Xoma Prepares for a Comeback
Executive Summary
Despite the early-90s failure of its first product, an anti-sepsis monoclonal antibody, Xoma Corp. has persisted in developing pharmaceuticals for endotoxin-related disorders. The firm has no intention of letting past failings, like the lack of a rapid diagnostic, sink it twice. So it's doing deals with diagnostics companies, and talking up recent research about endotoxins.